文献速递脑血管病

替格瑞洛与氯吡格雷联合阿司匹林治疗轻型缺血性卒中及短暂性脑缺血发作患者的比较:一项网状Meta分析

Comparison of Ticagrelor vs Clopidogrel in Addition to Aspirin in Patients With Minor Ischemic Stroke and Transient Ischemic Attack: A Network Meta-analysis.
PubMed 文献 · JAMA Neurol · 2022-01-01

该网状Meta分析纳入5项随机临床试验共22098例急性轻型缺血性卒中或短暂性脑缺血发作患者,比较替格瑞洛联合阿司匹林与氯吡格雷联合阿司匹林预防卒中复发或死亡的效果。结果显示两种双联抗血小板方案均优于单用阿司匹林,但两方案之间主要结局无统计学显著差异。

要点

  • 氯吡格雷联合阿司匹林与替格瑞洛联合阿司匹林均优于单用阿司匹林预防卒中复发和死亡。
  • 两种双联抗血小板方案在主要结局上无统计学显著差异(HR 0.94,95% CrI 0.78-1.13)。
  • 两种双联抗血小板方案的大出血发生率均高于单用阿司匹林。

核心结论

  • 阿司匹林联合替格瑞洛或氯吡格雷的双联抗血小板治疗均优于单用阿司匹林,但两种方案在主要结局(90天内卒中复发或死亡)上无统计学显著差异。

研究设计与样本

  • 研究为网状Meta分析,遵循PRISMA指南,检索MEDLINE、Embase和Cochrane数据库自建库至2021年2月,纳入5项随机临床试验,共分析22098例患者,其中氯吡格雷联合阿司匹林组5517例,替格瑞洛联合阿司匹林组5859例,阿司匹林组10722例。

主要发现

  • 氯吡格雷联合阿司匹林与替格瑞洛联合阿司匹林均优于单用阿司匹林预防卒中复发和死亡:氯吡格雷联合阿司匹林组HR 0.74(95% CrI 0.65-0.84),替格瑞洛联合阿司匹林组HR 0.79(95% CrI 0.68-0.91)。
  • 氯吡格雷联合阿司匹林与替格瑞洛联合阿司匹林在主要结局上无统计学显著差异(HR 0.94,95% CrI 0.78-1.13)。
  • 两种双联抗血小板方案的大出血发生率均高于单用阿司匹林。
  • 氯吡格雷联合阿司匹林与单用阿司匹林相比功能残疾风险降低(HR 0.82,95% CrI 0.74-0.91),与替格瑞洛联合阿司匹林相比功能残疾风险也降低(HR 0.85,95% CrI 0.75-0.97)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Dual antiplatelet therapy (DAPT) with clopidogrel and aspirin is effective in preventing recurrent strokes after minor ischemic stroke or transient ischemic attack (TIA). However, there is emerging evidence for the use of ticagrelor and aspirin, and the 2 DAPT regimens have not been compared directly. OBJECTIVE: To compare ticagrelor and aspirin with clopidogrel and aspirin in patients with acute minor ischemic stroke or TIA in the prevention of recurrent strokes or death. DATA SOURCES: MEDLINE, Embase, and Cochrane from database inception until February 2021. STUDY SELECTION: Randomized clinical trials that enrolled adults with acute minor ischemic stroke or TIA and provided the mentioned interventions within 72 hours of symptom onset, with a minimum follow-up of 30 days. DATA EXTRACTION AND SYNTHESIS: PRISMA guidelines for network meta-analyses were followed. Two reviewers independently extracted data and appraised risk of bias. Fixed-effects models were fit using a bayesian approach to network meta-analysis. Between-group comparisons were estimated using hazard ratios (HRs) with 95% credible intervals (95% CrIs). Surface under the cumulative rank curve plots were produced. MAIN OUTCOMES AND MEASURES: The primary outcome was a composite of recurrent stroke or death up to 90 days. Secondary outcomes include major bleeding, mortality, adverse events, and functional disability. A sensitivity analysis was performed at 30 days for the primary outcome. RESULTS: A total of 4014 citations were screened; 5 randomized clinical trials were included. Data from 22 098 patients were analyzed, including 5517 in the clopidogrel and aspirin arm, 5859 in the ticagrelor and aspirin arm, and 10 722 in the aspirin arm. Both clopidogrel and aspirin (HR, 0.74; 95% CrI, 0.65-0.84) and ticagrelor and aspirin (HR, 0.79; 95% CrI, 0.68-0.91) were superior to aspirin in the prevention of recurrent stroke and death. There was no statistically significant difference between clopidogrel and aspirin compared with ticagrelor and aspirin (HR, 0.94; 95% CrI, 0.78-1.13). Both DAPT regimens had higher rates of major hemorrhage than aspirin alone. Clopidogrel and aspirin was associated with a decreased risk of functional disability compared with aspirin alone (HR, 0.82; 95% CrI, 0.74-0.91) and ticagrelor and aspirin (HR, 0.85; 95% CrI, 0.75-0.97). CONCLUSIONS AND RELEVANCE: DAPT combining aspirin with either ticagrelor or clopidogrel was superior to aspirin alone, but there was no statistically significant difference found between the 2 regimens for the primary outcome.

来源:JAMA Neurol,查看原文。版权归原作者所有。

引用

  1. Lun R, Dhaliwal S, Zitikyte G, et al. Comparison of Ticagrelor vs Clopidogrel in Addition to Aspirin in Patients With Minor Ischemic Stroke and Transient Ischemic Attack: A Network Meta-analysis. JAMA Neurol. 2022. PMID: 34870698. doi:10.1001/jamaneurol.2021.4514

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。